RARE | Page 4 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

35.98

2.56

(256.00%)

content_middle

Previous Close:

33.42

52wk Range:

29.59 - 60.37

Market Capitalization:

0.00M

Shares Outstanding:

0.00M

content_right

October 6, 2014 - 11:29am | BOD & C-Suite Updates
BioTime (BTX) names new directors
September 8, 2014 - 9:31am | Out and About
Opexa Therapeutics (OPXA) to target rare disease Neuromyelitis optica - HOLD
August 18, 2014 - 6:25pm | Earnings
Fibrocell (NYSEMKT: FCSC) Q2/14 Earnings – Net Loss SLASHED 608.6%
August 18, 2014 - 1:59pm | Earnings
Stemline (STML) Q2/14 Earnings – Net Loss Slashed 33%
July 30, 2014 - 7:37am | Regulatory
Fate Therapeutics (FATE) FDA Clearance of IND for PROHEMA - BUY
June 13, 2014 - 9:23am | Regulatory
Fibrocell (NYSE MKT: FCSC) unit granted orphan drug status
April 29, 2014 - 9:06am | Research Notes
Bristol-Myers Squibb (BMW) acquires iPierian
April 1, 2014 - 11:50am | Out and About
First Evidence that Very Small Embryonic-Like Stem Cells (VSELs) from Human Adult Tissues is Multipotent
March 27, 2014 - 8:50am | Regulatory
bluebird bio (BLUE) 1st Patient Transplanted in P1/2 - BUY
November 16, 2013 - 6:39pm | Research Notes
Trial Status
October 29, 2013 - 8:42am | Research Notes
Stemline (STML) $3 M Collaboration for SL-401
October 28, 2013 - 8:45am | Regulatory
bluebird bio (BLUE) 1st Patient Transplanted in P2/3 ALD-102
September 20, 2013 - 9:25am | Research Notes
Cytori Therapeutics (CYTX), early data from scleroderma study
September 4, 2013 - 10:10am | Out and About
iPierian Spins-out True North Therapeutics
August 23, 2013 - 10:58am | Regulatory
Japan conducts first operation of liver cells transplant to baby
July 24, 2013 - 8:32am | Research Notes, Regulatory
Verastem (VSTM) FDA Orphan Drug Designation for Defactinib

VSTM
July 11, 2013 - 2:01pm | Research Notes
A beginning, Pharma is finally stepping up on stem cell therapies
July 8, 2013 - 11:29am
Harvard BIO (HBIO) Young Girl Given Bioengineered Windpipe Dies
June 19, 2013 - 10:31am | Research Notes, Financings
Bluebird bio (BLUE) Debuts with $90.9 M offering

BLUE
June 13, 2013 - 3:16pm | Out and About
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.